• Abstract

    Inflammatory bowel disease (IBD) causes persistent mucosal inflammation, and mounting evidence points to the intestinal microbiota's critical involvement in this process. New molecular techniques have also helped to identify dysbiosis in these individuals. Many potential probiotic product action mechanisms counteract IBD etiological causes. The study aimed to explain the benefits of probiotics for IBD and thoroughly evaluate current trials using probiotics to treat IBD in grownups. A specific search was done using specified keywords on October 1, 2011, using the supplied date range. Only English-language, full-text articles on clinical results for adult patients were addressed. Based on disease type and disease activity, the 41 eligible studies were classified. Pooled odds ratios were calculated only when there were many available randomized controlled trials per probiotic for a particular patient group. According to well-designed randomized controlled studies, few probiotics are effective in treating IBD at this time. It was only feasible to conduct meta-analyses on a limited number of studies, which yielded an overall risk ratio of 2.70 for inducing remission in active U.C. with Bifido fermented milk versus placebo or no adjuvant treatment. Very Specific Lactic Acid Bacteria (VSL#3) enables people to go into remission active U.C. compared to placebo. To support the favorable outcomes for inactive ulcerative colitis (U.C.), it is still a need to conduct better-conducted investigations in regard to the variety of drug VSL#3 in patients with both active and dormant U.C. U.C. based on intention-to-treat analyses by many independent research organizations. According to the existing data, probiotic usage in Crohn’s Disease (CD) has yet to be shown. The location and subtypes of certain diseases should be the focus of future research. Selecting probiotic strains for certain disease entities and illness sites will be easier with more knowledge of the mechanisms of probiotic strains and the etiology of IBD.

  • References

    1. Adamina M, Gerasimidis K, Sigall-Boneh R, Zmora O, de Buck van Overstraeten A, Campmans-Kuijpers M, Ellul P, Katsanos K, Kotze PG, Noor N & Schäfli-Thurnherr JN (2020) Perioperative dietary therapy in inflammatory bowel disease. Journal of Crohn's and Colitis, 14(4), 431-44. DOI: 10.1093/ecco-jcc/jjz160
    2. Asto, E., Mendez, I., Audivert, S., Farran-Codina, A. & Espadaler, J., (2019) The efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. Nutrients, 11(2), p.293. DOI: doi.org/10.3390/nu11020293
    3. Cui, H.H., Chen, C.L., Wang, J.D., Yang, Y.J., Cun, Y., Wu, J.B., Liu, Y.H., Dan, H.L., Jian, Y.T. & Chen, X.Q., (2004) Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World Journal of Gastroenterology, 10(10), p.1521. DOI: doi.org/10.3748%2Fwjg.v10.i10.1521.
    4. Dale HF, Rasmussen SH, Asiller ÖÖ & Lied GA (2019) Probiotics in irritable bowel syndrome: an up-to-date systematic review. Nutrients, 11(9), 2048. DOI: doi.org/10.3390/nu11092048
    5. Doman DB, Goldberg HJ & Golding MI (2008) “Ecologic niche” therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. Official journal of the American College of Gastroenterology| ACG, 103(1), 251-2.
    6. Dore MP, Bibbò S, Fresi G, Bassotti G & Pes GM (2019). Side effects associated with probiotic use in adult patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Nutrients, 11(12), 2913. DOI: doi.org/10.3390/nu11122913
    7. Fernández-Tomé S, Marin AC, Ortega Moreno L, Baldan-Martin M, Mora-Gutiérrez I, Lanas-Gimeno A, Moreno-Monteagudo JA, Santander C, Sánchez B, Chaparro M & Gisbert JP (2019). Immunomodulatory effect of gut microbiota-derived bioactive peptides on human immune system from healthy controls and patients with inflammatory bowel disease. Nutrients, 11(11), 2605. DOI: doi.org/10.3390/nu11112605
    8. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G & Campieri M (2007). High-dose probiotics for the treatment of active pouchitis. Diseases of the Colon & Rectum, 50, 2075-84. Doi: doi.org/10.1007/s10350-007-9068-4
    9. Gracie, D.J., Hamlin, P.J. & Ford, A.C., (2019). The influence of the brain–gut axis in inflammatory bowel disease and possible implications for treatment. The lancet Gastroenterology & hepatology, 4(8), pp.632-642. DOI: https://doi.org/10.1016/S2468-1253(19)30089-5
    10. Guslandi M (2010). Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. Journal of clinical gastroenterology, 44(5), 385. DOI: 10.1097/MCG.0b013e3181cb4233
    11. Guslandi M, Giollo P & Testoni PA (2003). A pilot trial of Saccharomyces boulardii in ulcerative colitis. European journal of gastroenterology & hepatology, 15(6), 697-8.
    12. Guslandi M, Mezzi G, Sorghi M & Testoni PA (2000). Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digestive diseases and sciences, 45, 1462-4. Doi: doi.org/10.1023/A:1005588911207
    13. Humbel F, Rieder JH, Franc Y, Juillerat P, Scharl M, Misselwitz B, Schreiner P, Begré S, Rogler G, von Känel R & Yilmaz B (2020). Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel diseases in remission. Clinical gastroenterology and hepatology, 18(9), 2019-29. DOI: doi.org/10.1016/j.cgh.2019.09.022
    14. Jakubczyk D, Leszczyńska K & Górska S (2020). The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review. Nutrients, 12(7), 1973. DOI: doi.org/10.3390/nu12071973
    15. Jakubczyk D, Leszczyńska K & Górska S (2020). The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review. Nutrients, 12(7), 1973. DOI: doi.org/10.3390/nu12071973
    16. Jha R, Das R, Oak S & Mishra P (2020). Probiotics (direct-fed microbials) in poultry nutrition and their effects on nutrient utilization, growth and laying performance, and gut health: A systematic review. Animals, 10(10), 1863. DOI: doi.org/10.3390/ani10101863
    17. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A & Arakawa Y (2004). Randomized placebo‐controlled trial assessing the effect of bifidobacteria‐fermented milk on active ulcerative colitis. Alimentary pharmacology & therapeutics, 20(10), 1133-41. doi.org/10.1111/j.1365-2036.2004.02268.x
    18. Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, Nasri F & Mazloomi SM (2020). Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Clinical Nutrition, 39(3), 789-819. DOI: https://doi.org/10.1016/j.clnu.2019.04.004
    19. Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M. & Wolff, C.,(2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 53(11), pp.1617-1623. DOI: doi.org/10.1136/gut.2003.037747
    20. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M & Farkkila M (2003). Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Alimentary pharmacology & therapeutics, (4), 509-15. Doi: doi.org/10.1046/j.1365-2036.2003.01465.x
    21. Kuzela L, Kascak M & Vavrecka A (2001). Induction and Maintenance of Remission With NonpathogenicEscherichia Coliin Patients With Pouchitis. Official journal of the American College of Gastroenterology| ACG, 96(11), 3218-9. DOI: 10.1111/j.1572-0241.2001.05294.x
    22. Laake KO, Line PD, Aabakken L, Løtveit T, Bakka A, Eide J, Røsetti A, Grzyb K, Bjørneklett A & Vatn MH (2003). Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scandinavian journal of gastroenterology, 38(4), 409-14. Doi: doi.org/10.1080/00365520310000906
    23. Lomer MC, Wilson B & Wall CL (2023). British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease. Journal of Human Nutrition and Dietetics, 36(1), 336-77. DOI: doi.org/10.1111/jhn.13054
    24. Malinowski B, Wiciński M, Sokołowska MM, Hill NA & Szambelan M (2020) The rundown of dietary supplements and their effects on inflammatory bowel disease—A review. Nutrients, 12(5), 1423. DOI: doi.org/10.3390/nu12051423
    25. Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, Cadiot G, Soulé JC, Bourreille A, Metman E, Lerebours E. (2006). Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut, 55(6), 842-7. Doi: /doi.org/10.1136/gut.2005.076604
    26. Matthes H, Krummenerl T, Giensch M, Wolff C & Schulze J (2010). Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC complementary and alternative medicine, 10, 1-8. DOI: doi.org/10.1186/1472-6882-10-13
    27. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M & Kamm MA (2004). Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis. Gut. 1; 53(1), 108-14. Doi: doi.org/10.1136/gut.53.1.108
    28. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA & Petersen AM (2019). Escherichia coli pathobionts associated with inflammatory bowel disease. Clinical microbiology reviews, 32(2), 10-128. DOI: https://doi.org/10.1128/cmr.00060-18
    29. Pavel FM, Vesa CM, Gheorghe G, Diaconu CC, Stoicescu M, Munteanu MA, Babes EE, Tit DM, Toma MM & Bungau S (2021) Highlighting the relevance of gut microbiota manipulation in inflammatory bowel disease. Diagnostics, 11(6), 1090. DOI: doi.org/10.3390/diagnostics11061090
    30. Prantera C, Scribano ML, Falasco G, Andreoli A & Luzi C (2002) Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut, 51(3), 405-9. Doi: doi.org/10.1136/gut.51.3.405
    31. Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA & Rath HC (2004). Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC gastroenterology, 4(1), 1-4. Doi: doi.org/10.1186/1471-230X-4-5
    32. Somineni HK & Kugathasan S (2019) The microbiome in patients with inflammatory diseases. Clinical Gastroenterology and Hepatology. 17(2), 243-55. DOI: doi.org/10.1016/j.cgh.2018.08.078
    33. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P & Tandon RK (2009). The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical gastroenterology and hepatology, 7(11), 1202-9. DOI: doi.org/10.1016/j.cgh.2009.07.016
    34. Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV & Morgan RL (2020). AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology, 159(2), 697-705. DOI: doi.org/10.1053/j.gastro.2020.05.059
    35. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA & Modeo ME (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL# 3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. The American journal of gastroenterology, 105(10), 2218. DOI: doi.org/10.1038%2Fajg.2010.218
    36. Wildt S, Nordgaard I, Hansen U, Brockmann E & Rumessen JJ (2011). A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. Journal of Crohn's and Colitis, 5(2), 115-21. DOI: doi.org/10.1016/j.crohns.2010.11.004
    37. Yao S, Zhao Z, Wang W & Liu X (2021). Bifidobacterium longum: protection against inflammatory bowel disease. Journal of immunology research. DOI: doi.org/10.1155/2021/8030297
    38. Zhang XF, Guan XX, Tang YJ, Sun JF, Wang XK, Wang WD & Fan JM (2021). Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: A systematic review and meta-analysis. European journal of nutrition, 60, 2855-75. DOI: doi.org/10.1007/s00394-021-02503-5
    39. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V & Armuzzi A (2006). Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary pharmacology & therapeutics, 23(11), 1567-74. DOI: doi.org/10.1111/j.1365-2036.2006.02927.x

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 Multidisciplinary Reviews

How to cite

Upadhye, V. J., Ballal, S., Singh, S., & Rani, R. (2024). A systematic assessment on the influence of probiotics on patients with Inflammatory Bowel Disorder. Multidisciplinary Reviews, 6, 2023ss022. https://doi.org/10.31893/multirev.2023ss022
  • Article viewed - 115
  • PDF downloaded - 45